Skip to content

Ketamine for PTSD: all studies

Page 5 of 13: studies 41 to 50 of 130, newest first. Back to the ketamine for PTSD overview

Research

The Induction of Dissociative States: A Meta-Analysis.

Biological Psychiatry Global Open Science July 1, 2025 Benjamin Brake, Lillian Wieder, Natasha Hughes et al. 5 citations

Dissociative states, characterized by discontinuities in awareness and perception, occur in a diverse array of psychiatric disorders and contexts. These states have been experimentally modeled in the laboratory through various induction methods, but relatively little is known about the efficacy and comparability of different experimental methods. In this meta-analysis, we quantified...

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

DOI: 10.1016/j.jad.2025.119632 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonists Posttraumatic Stress Treatment resistant depression +6

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Journal of Psychopharmacology June 5, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 19 citations

We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...

Association Between Receipt of Ketamine vs Etomidate for Emergency Tracheal Intubation and Symptoms of Posttraumatic Stress Disorder at 12 Months.

CHEST critical care June 1, 2025 Lucas C Wollenman, Austin M Tipold, Matthew W. Semler et al. 1 citation

One of 3 patients in the ICU receiving mechanical ventilation demonstrates posttraumatic stress disorder (PTSD). A single dose of ketamine has been shown to reduce PTSD symptoms in outpatients with chronic PTSD, but its long-term effect is unknown in patients who are critically ill and mechanically ventilated. Is ketamine, when used for induction of anesthesia before emergency tracheal...

The Effect of Ketamine-Assisted Group Therapy on Treatment-Resistant Mental Health Conditions in Firefighters: A Prospective Observational Case Series.

Journal of Occupational and Environmental Medicine June 1, 2025 Vivian Wl Tsang, Michelle Cq Lin, Cassandra M Choles et al. 4 citations

Firefighters display elevated risk for diagnoses of mental health illnesses. Psychedelic-assisted therapies show promise in the treatment of clinically challenging conditions. This observational case series analyzed data from firefighters with mental health diagnoses who participated in a 12-week ketamine-assisted group therapy treatment plan. Questionnaire scores (Generalized Anxiety Disorder...

Molecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD.

Psychopharmacology June 1, 2025 Nathan J Wellington, Ana P. Bouças, Jim Lagopoulos et al. 16 citations

Existing studies predominantly focus on the molecular and neurobiological mechanisms underlying Ketamine's acute treatment effects on post-traumatic stress disorder (PTSD). This emphasis has largely overlooked its sustained therapeutic effects, which hold significant potential for the development of targeted interventions. This systematic review examines the pharmacokinetic and pharmacodynamic...

Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System.

CNS Drugs June 1, 2025 Sijia Zhang, Houtan Afshar, Peter J. Colvonen et al. 1 citation

Ketamine and esketamine are increasingly used to manage treatment-resistant depression and have also been shown to reduce symptoms of posttraumatic stress disorder (PTSD). Little is known about how common comorbidities in the veteran population, such as traumatic brain injury (TBI) or obstructive sleep apnea (OSA), may influence ketamine and esketamine treatment outcomes. In this retrospective...

DOI: 10.1007/s40263-025-01180-w (opens in new tab) Full text (opens in new tab) Ketamine therapy Veterans mental health PTSD Treatment Depression treatment +1

Methylome and transcriptome functional analysis identifies key biomarkers in ketamine’s sustained therapeutic effect on PTSD

medRxiv May 27, 2025 Nathan J Wellington, Ana Paula Bouças, Paul Schwenn et al. 1 citation preprint

Abstract Background Ketamine has emerged as a rapid-acting therapeutic option for post-traumatic stress disorder (PTSD); however, its ability to sustain long-term therapeutic outcomes remains poorly understood. Identifying molecular biomarkers predictive of a sustained response to ketamine may enhance personalised treatment strategies. This study investigates the epigenetic and transcriptomic...

Temporal Immune Effects of Oral Ketamine on PTSD: Transcriptomic Evidence of Short-Term Inflammation Suppression and Long-Term Immune Remodelling

medRxiv Preprint Server May 26, 2025 Nathan J Wellington, Bonnie L. Quigley, Ana P. Bouças et al. preprint

Ketamine’s rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs)...

DOI: 10.1101/2025.05.26.25328370 (opens in new tab) Full text (opens in new tab) Ketamine therapy PTSD Treatment Mental health treatment Ketamine For PTSD +14

Updated Findings on the Efficacy of Combined Subanesthetic Ketamine Infusion and Cervical Sympathetic Blockade as a Symptomatic Treatment of PTSD/TBI in a Special Forces Patient with a 2-year Follow-up: A Case Report.

Journal of special operations medicine : a peer reviewed journal for SOF medical professionals April 30, 2025 Eugene Lipov, Zubin Sethi, Hunter Rolain

Posttraumatic stress disorder (PTSD)/blast traumatic brain injury (bTBI) in a Special Operations Forces (SOF) cohort has been shown to be successfully treated using a cervical sympathetic blockade (CSB)/ketamine infusion (KI) combination, termed the SOF method. In a prior case report, the patient was followed for 1 year. This report followed the same patient for a total of 720 days and found...

DOI: 10.55460/2QC5-PHPF (opens in new tab) Full text (opens in new tab) Sof Btbi Cervical sympathetic blockade Ketamine infusion +5